DD

Business profile & competitive position

DuPont de Nemours, Inc. (DD) sits in the Basic Materials sector, specifically the Chemicals industry. It is a provider of advanced solutions across healthcare, water, construction, and industrial end markets. The company now reports through two segments: Healthcare & Water Technologies and Diversified Industrials, after treating its Electronics, Aramids, and historical M&M businesses as discontinued operations. The continuing portfolio includes medical packaging and devices, water filtration and purification products, building-envelope and interior solutions, and industrial adhesives, lubricants, engineered shapes, and printing plates.

The company’s margin and return figures tell a mixed story about durable competitive strength. Net margin is only 0.7%, and ROE is 0.3%. Those are extremely low for a company of this size, suggesting that DuPont’s earnings power has been squeezed by recent portfolio transitions, legacy charges, and cost-sharing obligations. A chemicals and materials incumbent normally derives a moat from scale, intellectual property, and long-term customer relationships, and DuPont does own roughly 6,100 patents and patent applications globally, with about 4,700 linked to continuing operations and more than 70% of the continuing-operations patent estate having a remaining term of more than five years. Still, the thin 0.7% net margin and 0.3% ROE imply that the company is not currently extracting strong economic profit from those assets. Investors should treat the moat as historically meaningful but operationally weakened until the remaining businesses show higher normalized profitability.

Financial posture

DuPont’s current financial profile is unusual. The market capitalization is $18.4 billion, yet the trailing P/E ratio is 296.7. That multiple is far above typical chemicals valuations and reflects depressed trailing earnings rather than premium growth expectations. The net margin of 0.7% and ROE of 0.3% reinforce the same point: the denominator in the P/E is small, pushing the ratio higher. A beta of 1.08 means the stock has moved roughly in line with the broader equity market, slightly more volatile but not dramatically so.

For a company that has been shrinking its operational footprint through divestitures, the key financial question is what remains. The new DuPont is defined by two reportable segments and a smaller asset base, yet the headline profitability has not rebounded. The $18.4 billion valuation therefore looks like a bet on post-divestiture normalization rather than a reward for current performance. Analysts typically want to see whether management can translate the narrower, specialty-focused portfolio into margins that justify the remaining enterprise value.

Strategic priorities & outlook

DuPont’s most recent 10-K filing outlines four near-term priorities. First, the company expects to complete the previously announced sale of the Aramids business to Arclin around the end of the first quarter of 2026, subject to customary closing conditions and regulatory approvals. Second, it is trying to realize the intended benefits of the Electronics Separation, including the intended tax treatment and the contractual allocation of certain liabilities to Qnity. Third, management has committed to executing the $2 billion share buyback authorization announced on November 6, 2025. Fourth, DuPont continues to manage an arrangement to share future eligible PFAS costs among DuPont, Corteva, and Chemours, including related litigation and remediation exposures.

Operationally, the company realigned into two reportable segments effective in the fourth quarter of 2025 and recast financial statements as if the M&M, Aramids, and Electronics separations had occurred on January 1, 2023. At December 31, 2025, DuPont had subsidiaries in about 50 countries, manufacturing operations in about 20 countries, and approximately 15,000 employees worldwide, including about 1,700 dedicated to the Aramids business. The 6,100-patent portfolio gives management something to monetize through continuing specialty products, but the near-term investment narrative is dominated by whether the Aramids sale closes cleanly and whether the PFAS cost-sharing framework prevents future liabilities from overwhelming earnings.

Macro & geopolitical exposure

As a Basic Materials / Chemicals company with manufacturing in roughly 20 countries and subsidiaries in about 50, DuPont is exposed to several macro factors. Commodity prices and feedstock costs matter: many chemical products depend on oil, natural gas, and petrochemical derivatives, so energy price shifts influence margins. Currency translation is also relevant, because a large share of sales and production occurs outside the United States. Trade policy, tariffs, and cross-border supply-chain rules can affect both input costs and the movement of finished goods. Regulatory exposure is elevated for chemicals companies, especially around environmental compliance, water discharge, and product safety. DuPont’s PFAS cost-sharing arrangement illustrates that litigation and remediation risk are active balance-sheet concerns, not abstract industry risks. Finally, end-market cyclicality in construction, industrial manufacturing, and healthcare demand can swing revenues quarter to quarter.

Recent developments

Recent news around DuPont has included both strategic product announcements and institutional trading activity. On October 23, 2026, Zacks reported that DuPont expanded its bioprocessing portfolio with new chromatography media, a development consistent with the healthcare and water-related identity of the continuing business. The same day, Defense World reported that Integrated Advisors Network LLC purchased 4,600 shares of DuPont stock. More recently, on October 26, 2026, Defense World noted that Financial Management Professionals Inc. acquired shares, while MarketBeat included DuPont in a list of beaten-down growth stocks trading like value plays as capital chased mega-caps. These headlines do not carry fundamental ratings, but they do indicate that portfolio managers and media coverage are watching the stock closely as it trades at a compressed current-earnings multiple.

Earnings behavior & post-earnings drift

DuPont’s earnings track record over the past eight quarters is statistically striking. The company has beaten estimates in all eight of the last reported quarters, a 100% beat rate, with an average surprise of 171.1%. Looking at the last four releases, the headline figures show how unusual the EPS results have been relative to the unofficial consensus. On November 6, 2025, DuPont reported EPS of $3.27 against an estimate of $0.4656, a 602.3% surprise; on February 10, 2026, EPS came in at $1.38 versus $1.29, a 7% surprise; on May 5, 2026, EPS was $1.65 against $0.4881, a 238% surprise; and on August 4, 2026, EPS was $1.88 versus $1.76, a 6.8% surprise.

The stock has also exhibited positive post-earnings drift. Across the last eight quarters, the average 5-day move after earnings has been 2.83%, classified as an upward drift. In the most recent release, the stock gained 3.11% the next day and 1.09% over the following five days. The May 2026 and February 2026 releases produced 1.69% and 4.25% next-day gains, respectively, and 2.64% and 3.88% five-day follow-throughs. On the surface, the data suggest that the market has consistently underpriced the earnings outcome, but the extreme average surprise of 171.1% is heavily skewed by a couple of massive beats. The next earnings date to watch is November 3, 2026, before the open, with the consensus EPS estimate at $1.87. Traders and analysts will be asking whether the margin structure has improved enough to produce another clean beat, or whether the guidance will reveal more pressure from legacy liabilities and divestiture costs.

For a deeper dive into how professional analysts are interpreting the company’s valuation reset, legacy exposures, and upcoming earnings event, view the full institutional verdict on DuPont de Nemours.